Key statistics dashboard for Humacyte, Inc. (HUMA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Stock Data
| Price | $0.57 |
| Market Cap | $96M |
| Beta | 2.10 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.12 |
| Price / Book | 4.27 |
| P/S | 45.16 |
| P/FCF | -0.98 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -666.81% |
| EBIT Margin | -4075.34% |
| EBITDA Margin | -3755.68% |
| Operating Margin | -5240.78% |
| Net Margin | -4560.82% |
Financial Health
| Current Ratio | 6.21 |
| Quick Ratio | 5.74 |
| Cash Ratio | 5.35 |
| Debt / Equity | 2.12 |
| Debt / Assets | 47.93% |
| Interest Coverage | -10.80 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -10.46 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 0.13 |
| Cash per share | 0.34 |
| FCF per share | -0.42 |
| Tangible Book Value per share | 0.13 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.91 |
Related companies: ACHV · ARCT · AVIR · FHTX · IMRX · NAUT · SGMT
Explore sector: Healthcare · Biotechnology
More sections of HUMA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks